About R&D

Our key contribution is to discover and develop innovative biological medicines and make them accessible to patients throughout the world.

In 1923, our Danish founders began a journey to change diabetes. We began by developing insulin and have for the past 90 years pioneered therapeutic proteins to address unmet medical needs. Our passion is to turn novel scientific discoveries into new protein therapeutics that improve the treatment options of people living with diabetes, obesity, haemophilia, growth disorders and inflammation.


Our passion for proteins

Collaborating for effective treatment solutions

Novo Nordisk R&D is a global organisation with sites in Denmark, China, US and India. We work seamlessly across our sites to share inspiration, exchange new ideas and apply a broad experience base to research problem-solving. In order to bring even more innovative science into our clinical portfolio, we also partner with external biotech and academic researchers whose ideas and scientific discoveries complement our protein expertise and clinical development know-how.

Listen to our Chief Science Officer, Mads Krogsgaard Thomsen: Our protein competencies 

  •  

Future treatments

Novo Nordisk has a strong portfolio of treatments in development
R&D Pipeline 


  •  
  •  

Bioethics first

Novo Nordisk achieves top rating in Dow Jones Sustainability Index for ninth year in a row!

  •  
  •  

Among world's best science employers

Novo Nordisk ranked as world's 4th best science employer in Top Employer survey conducted annually by Science Magazine

 
  •  
  •  

Learn more about our commitment to people with diabetes:

DAWN2 Study (Diabetes, Attitudes, Wishes and Needs)

Changing Diabetes® 

Novo Nordisk World Diabetes Foundation  

  •  
  •  

Learn more about our commitment to people with haemophilia

HERO - (Haemophilia Experiences, Results and Opportunities)
 
Changing Possibilities in Haemophilia® 

Novo Nordisk Haemophilia Foundation


  •